Scientists at Washington University School of Medicine have created an innovative antibody-based therapeutic system that self-assembles within the body through click chemistry, leading to improved cancer treatment outcomes in murine models. This modular strategy effectively targets various tumor receptors, addressing a significant drawback of traditional antibody-drug conjugates. In studies involving pancreatic cancer, nearly 90% of the treated mice survived for 120 days, in contrast to less than 80 days for conventional therapies. This platform holds the potential to expedite the application of existing FDA-approved medications while paving the way for more tailored cancer treatment approaches in upcoming clinical trials.
